Zimmer sued by Genzyme over knee treatment; Biotronik's Selectra launched in the U.S.;

> Genzyme, which was bought by Sanofi-Aventis this month, is suing Zimmer Holdings and Anika Therapeutics alleging the companies' treatments for arthritic knee pain infringe a patent. Story

> Biotronik has announced the U.S. market release of the Selectra left ventricular lead delivery system. Selectra delivers a significant advancement in lead placement systems for cardiac resynchronization therapy devices. Biotronik release

>  Drug-eluting stents for hearts have added as much as $1.57 billion to U.S. health costs since their introduction in 2003, U.S. researchers said on Monday. Story

> Cepheid announced it has received clearance from the FDA to market Xpert Flu. The diagnostic test, which runs on Cepheid's GeneXpert System, simultaneously detects and differentiates Influenza A, Influenza B and the 2009 H1N1 influenza virus in about one hour. Cepheid release

> Lantis Laser has signed the final definitive agreement to merge with TAG Minerals. TAG's management believes that with the price of gold breaking through the $1,500 an ounce barrier, the timing is good for the company to gear up and transition to full-scale mining operations in Zimbabwe. Lantis is developing high-resolution, light-based imaging modalities for dentistry that can detect decay and microstructural defects at an early stage and, unlike x-ray, do not emit potentially harmful radiation. Lantis Laser release

> D Medical Industries subsidiary Spring Health Solutions has obtained Canadian Medical Devices Conformity Assessment System certification for its diabetes drug delivery system--Universal Detach Detect Infusion Sets. The company will apply for Health Canada approval of the device. Report

And Finally... The incidence of diabetes in dogs has increased 200 percent over the past 30 years. However, University of Missouri veterinarians are changing the way veterinarians treat diabetes in animals by adapting a device used to monitor glucose in humans. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.